Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck and Takeda form US and Japan CNS alliance

Lundbeck and Takeda form an alliance to develop and commercialise novel CNS compounds in the US and Japan for the treatment of mood and anxiety disorders

Danish pharmaceutical company Lundbeck and Japan-headquartered Takeda have formed an alliance to develop and commercialise novel CNS compounds in the US and Japan for the treatment of mood and anxiety disorders.

Lundbeck has several compounds in its pipeline and the partnership will at first focus on co-development and co-commercialisation of the two most advanced: LU AA21004 and LU AA24530. The agreement sets out an option under certain conditions to include two other compounds of the same class in earlier stages of development.

Both later-stage compounds belong to a new chemical class and have demonstrated fast onset of effect and increased efficacy. The most advanced compound, LU AA21004, is currently in clinical phase II development for the treatment of major depressive disorder (MDD). Lundbeck says the clinical trials will be finalised, opened and announced in Q4 2007.

Per the agreement, Lundbeck will receive an initial payment of USD 40m and a potential maximum of USD 345m in additional development milestone payments.

Both firms will complete development programmes, with Takeda funding sales and the majority of the remaining development activities. 

Lundbeck will receive a share of the revenue generated in the US and Japan, as well as royalty payments on Takeda's share of revenues. Other financial details were undisclosed.

Yasuchika Hasegawa, president and CEO of Takeda, said: "We are delighted to have reached an agreement with one of the strongest global players in central nervous system research. We believe the [novel] compounds have the potential to demonstrate substantial benefits compared with existing therapies and that they willÖ enhance our CNS franchise, which is one of our core therapeutic areas."

Dr Claus Braestrup, president and CEO of Lundbeck, said: "The agreement provides a unique opportunity for Lundbeck to build a commercial presence both in the US and in Japan with the support of a strong partner, while we continue to utilise our own European and international platform outside the US and Japan to commercialise the compounds."

5th September 2007

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Spirit

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Live webinar:
The power of a good story: Turn your insights into effective storytelling with data visualisation...
clinical research org
The important role of CROs in shaping the future of clinical research across Europe
Looking at the impact of COVID-19 on clinical research activities...
What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...

Infographics